SS
IMDX

Steve Schonfeld’s Insight Molecular Diagnostics IMDX Stock Holding History

Steve Schonfeld’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-985
Closed -$4.53K – 2139
2023
Q2 		$4.53K Sell
985
-90
-8% -$453 ﹤0.01% 1947
2023
Q1 		$7.62K Sell
1,075
-20,120
-95% -$149K ﹤0.01% 1878
2022
Q4 		$136K Sell
21,195
-16,290
-43% -$180K ﹤0.01% 2108
2022
Q3 		$547K Sell
37,485
-10,385
-22% -$180K ﹤0.01% 1688
2022
Q2 		$862K Sell
47,870
-2,665
-5% -$60.6K 0.01% 1086
2022
Q1 		$1.51M Sell
50,535
-1,040
-2% -$33.3K 0.01% 839
2021
Q4 		$2.24M Sell
51,575
-11,973
-19% -$689K 0.02% 674
2021
Q3 		$4.52M Sell
63,548
-5,902
-8% -$543K 0.05% 471
2021
Q2 		$7.97M Sell
69,450
-11,691
-14% -$1.14M 0.08% 341
2021
Q1 		$8.42M Buy
81,141
+74,771
+1,174% +$7.1M 0.1% 272
2020
Q4 		$304K Buy
+6,370
New +$234K ﹤0.01% 1201
2019
Q3 		– Sell
-9,525
Closed -$474K – 1172
2019
Q2 		$474K Sell
9,525
-33,915
-78% -$2.82M 0.02% 649
2019
Q1 		$3.43M Buy
+43,440
New +$2.8M 0.12% 231

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Steve Schonfeld's IMDX Position: Q3 2023 in Review

Steve Schonfeld sold out of Insight Molecular Diagnostics (IMDX) in Q3 2023, closing a stake of 985 shares — an estimated $4.53K sold.

Steve Schonfeld first reported a position in IMDX in Q1 2019 and held it in 13 quarters. The position peaked at $8.42M in Q1 2021. 30 funds tracked by Wall St. Rank hold IMDX as of Q3 2023.

  • Steve Schonfeld reported no remaining Insight Molecular Diagnostics position as of Q3 2023 after selling out during the quarter.
  • Steve Schonfeld sold 985 Insight Molecular Diagnostics shares in Q3 2023, an estimated $4.53K.
  • Steve Schonfeld first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 13 quarters.
  • Steve Schonfeld's Insight Molecular Diagnostics position peaked at $8.42M in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.